After screenings with KSHV+ lymphoma systems, we identified 009P1 and 009P2, a pair of epimers, displaying better anticancer activities for KSHV+ lymphomas than current HDACs or BRD4 inhibitors even at low nanomolar concentrations, and with no visible toxicity on normal cells. This evidence concerns the gene BRD4 and lymphoma.